We hypothesized a priori that tumor subtype, higher grade/proliferation, and selected treatment components (platinum in TNBC, dual anti-HER2 therapy) would be associated with higher pCR rates, whereas higher baseline clinical stage would predict lower pCR. Here, ERBB2 is linked to neoplasm.